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1. INTRODUCTION {#tbed13051-sec-0001}
===============

Seneca Valley virus 1 (SVV‐1) is the only known virus belonging to the species *Senecavirus A*, genus *Senecavirus*, within the family *Picornaviridae* (Knowles et al., [2012](#tbed13051-bib-0023){ref-type="ref"}). It is a non‐enveloped, single‐stranded, positive‐sense RNA virus recently associated with vesicular disease in swine in Brazil, the USA, China, Canada, Colombia and Thailand (Hause, Myers, Duff, & Hesse, [2016](#tbed13051-bib-0016){ref-type="ref"}; Pasma, Davidson, & Shaw, [2008](#tbed13051-bib-0027){ref-type="ref"}; Saeng‐chuto, Rodtian, Temeeyasen, Wegner, & Nilubol, [2017](#tbed13051-bib-0030){ref-type="ref"}; Sun, Vannucci, Knutson, Corzo, & Marthaler, [2017](#tbed13051-bib-0501){ref-type="ref"}; Vannucci et al., [2015](#tbed13051-bib-0032){ref-type="ref"}; Wu et al., [2016](#tbed13051-bib-0034){ref-type="ref"}). Clinical signs include vesicles on the snout and coronary band, lameness, anorexia, lethargy and fever (Hause et al., [2016](#tbed13051-bib-0016){ref-type="ref"}). These are indistinguishable from those of other notifiable vesicular diseases including foot‐and‐mouth disease (FMD) (Alexandersen, Zhang, Donaldson, & Garland, [2003](#tbed13051-bib-0001){ref-type="ref"}; Dekker, [2000](#tbed13051-bib-0008){ref-type="ref"}; Kitching, [2002](#tbed13051-bib-0021){ref-type="ref"}) which can have a high economic impact (Knight‐Jones & Rushton, [2013](#tbed13051-bib-0022){ref-type="ref"}).

Rapid and accurate detection of SVV‐1 is necessary to confirm the disease causing agent, and to initiate the implementation of control processes. Virus isolation on cell cultures (Hales et al., [2008](#tbed13051-bib-0015){ref-type="ref"}; Knowles et al., [2012](#tbed13051-bib-0023){ref-type="ref"}), conventional and real‐time RT‐PCR (rRT‐PCR) assays (Bracht, O\'Hearn, Fabian, Barrette, & Sayed, [2016](#tbed13051-bib-0006){ref-type="ref"}; Dall Agnol, Otonel, Leme, Alfieri, & Alfieri, [2017](#tbed13051-bib-0007){ref-type="ref"}; Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}; Gimenez‐Lirola et al., [2016](#tbed13051-bib-0013){ref-type="ref"}) and full genome sequencing (Hales et al., [2008](#tbed13051-bib-0015){ref-type="ref"}) have all been used to identify and investigate SVV‐1 isolates. A number of accurate and sensitive rRT‐PCR methods have been developed, targeting the viral polymerase 3D region (Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}), the VP1 coding region (Bracht et al., [2016](#tbed13051-bib-0006){ref-type="ref"}), and the 5′ untranslated region (5′‐UTR) (Gimenez‐Lirola et al., [2016](#tbed13051-bib-0013){ref-type="ref"}). However, diagnosis via these methods relies on the transport of samples under appropriate conditions from the point of collection to centralized laboratory settings, which may add a significant time delay and favour the spread of disease, particularly considering that modes of transmission have not yet been fully elucidated (Yoon, [2015](#tbed13051-bib-0035){ref-type="ref"}).

The development of rapid, cost‐effective diagnostic assays that can be used at the point of sample collection has been identified as a gap in preparedness for the control of SVV‐1 (Yoon, [2015](#tbed13051-bib-0035){ref-type="ref"}). Reverse transcription loop‐mediated isothermal amplification (RT‐LAMP) is able to rapidly amplify RNA with high specificity and efficiency under isothermal conditions at a single temperature, for example in a water bath (Notomi et al., [2000](#tbed13051-bib-0025){ref-type="ref"}), and allows the simple, rapid and cost‐effective detection of disease causing agents at the point of sample collection. A number of LAMP assays have been developed for veterinary pathogens such as foot‐and‐mouth disease virus (FMDV) (Dukes, King, & Alexandersen, [2006](#tbed13051-bib-0009){ref-type="ref"}; Howson et al., [2017](#tbed13051-bib-0018){ref-type="ref"}), African horse sickness virus (Fowler et al., [2016](#tbed13051-bib-0011){ref-type="ref"}) and African swine fever (James et al., [2010](#tbed13051-bib-0019){ref-type="ref"}), and some shown to be effective when deployed in field settings using simple sample preparation methods (Howson et al., [2017](#tbed13051-bib-0018){ref-type="ref"}). This study describes the development of two RT‐LAMP assays using lyophilized reagents, targeting the 5′‐untranslated region (5′UTR) and virus protein (VP) 3‐1 regions for the detection of SVV‐1, and performed on a portable real‐time fluorometer suitable for field use.

2. MATERIALS AND METHODS {#tbed13051-sec-0002}
========================

2.1. Ethics {#tbed13051-sec-0003}
-----------

Samples used in this study (Table [1](#tbed13051-tbl-0001){ref-type="table"}) were archival samples previously submitted to the World Reference Laboratory for FMD (WRLFMD; The Pirbright Institute, UK).

###### 

Seneca valley virus 1 cell‐culture isolates used for bench validation of the RT‐LAMP assays

  Sample name    Virus   Origin                Date of collection   P1 *T* ~p~   P1 *T* ~a~   P2 *T* ~p~   P2 *T* ~a~   SVV‐1 rRT‐PCR[a](#tbed13051-note-0002){ref-type="fn"}
  -------------- ------- --------------------- -------------------- ------------ ------------ ------------ ------------ -------------------------------------------------------
  NC‐88‐23626    SVV‐1   North Carolina, USA   1988                 06:45        87.7         08:00        86.3         21.90
  NJ‐90‐10324    SVV‐1   New Jersey, USA       1990                 06:30        87.7         06:30        86.3         21.04
  CA‐01‐131395   SVV‐1   California, USA       2001                 06:15        87.9         06:15        86.0         19.05
  LA‐97‐1278     SVV‐1   Louisiana, USA        1997                 05:45        87.9         07:00        86.3         19.89
  IA‐89‐47552    SVV‐1   Iowa, USA             1989                 06:00        87.7         06:15        86.4         19.40
  IL‐92‐48963    SVV‐1   Illinois, USA         1992                 06:45        87.9         06:30        86.2         20.94
  MN‐88‐36695    SVV‐1   Minnesota, USA        1988                 06:30        87.8         06:15        86.3         20.20

P1: primer set 1, P2: primer set 2, n/d: not done.

SVV‐1 samples were diluted 1/100 in negative pig epithelium tissue suspension, and all samples underwent RNA extraction. rRT‐PCR results are the means of two replicates.

John Wiley & Sons, Ltd

2.2. Virus isolates {#tbed13051-sec-0004}
-------------------

SVV‐1 cell culture isolates were obtained from archival stocks held in WRLFMD repository (Table [1](#tbed13051-tbl-0001){ref-type="table"}). For evaluation of direct detection, clinical samples were not available for this study, and therefore isolates were diluted 1/100 in negative pig epithelium tissue suspension (10% \[w/v\] diluted in M25 phosphate buffered saline: 35 mM Na~2~HPO~4~, 5.7 mM KH~2~PO~4~; pH 7.6). This was to simulate an original suspension (OS) sample that would be prepared by homogenization of swine epithelium tissue either in the field, for example using the SVANODIP® Ag Extraction kit (Svanova), or in the laboratory, before testing. A panel of other viruses that cause similar clinical signs to SVV‐1, including swine vesicular disease virus (SVDV): UKG/179/73 and ITL/16/2006; FMD virus (FMDV): O/MAY/13/2012, A/ZAM/1/2015, SAT 2/ZAM/2/2015, SAT 3/ZAM/3/2015, ASIA 1/PAK/37/2015; vesicular stomatitis New Jersey virus (VSNJV): 29344/Colombia/2000; vesicular stomatitis Indiana virus (VSIV): 29356/Colombia/2000; and African swine fever virus (ASFV): W2/16/01 was used to evaluate the specificity of the SVV‐1 RT‐LAMP.

2.3. RT‐LAMP primer design {#tbed13051-sec-0005}
--------------------------

Thirty‐nine published SVV‐1 full genomes (Accession numbers: [DQ641257](DQ641257), [KC667560](KC667560), [KT321458](KT321458), [KY419132](KY419132), [KY038016](KY038016), [KX377924](KX377924), [KX857728](KX857728), [KY747512](KY747512), [KY747511](KY747511), [KY747510](KY747510), [KX751945](KX751945), [KX751944](KX751944), [KX751943](KX751943), [KT757282](KT757282), [KT757281](KT757281), [KT757280](KT757280), [KX778101](KX778101), [KX019804](KX019804), [KU058183](KU058183), [KU058182](KU058182), [KU359214](KU359214), [KU359213](KU359213), [KU359212](KU359212), [KU359211](KU359211), [KU359210](KU359210), [KR063109](KR063109), [KR063108](KR063108), [KR063107](KR063107), [KY486165](KY486165), [KY486164](KY486164), [KY486163](KY486163), [KY486162](KY486162), [KY486161](KY486161), [KY486160](KY486160), [KY486159](KY486159), [KY486158](KY486158), [KY486157](KY486157), [KY486156](KY486156), [KY486166](KY486166)) and ten unpublished SVV‐1 full genomes ([KU954090](KU954090), [KU954089](KU954089), [KU954088](KU954088), [KU954087](KU954087), [KU954086](KU954086), [KX751946](KX751946), [KX223836](KX223836), [KX173340](KX173340), [KX173339](KX173339), [KX173338](KX173338)) were obtained from GenBank (<http://www.ncbi.nlm.nih.gov>), and used for design of the RT‐LAMP primers. Sequences were aligned in ClustalX (v.2.0.10) and a consensus sequence was generated. LAMP Designer (OptiGene Ltd, UK) was used to design six sets of RT‐LAMP primers, three with GenBank accession [DQ641257](DQ641257) as a reference: primer sets 1‐3 (P1‐P3), and three with the consensus sequence as a reference: primer sets 4‐6 (P4‐P6).

2.4. RNA extraction {#tbed13051-sec-0006}
-------------------

RNA was extracted using the MagMAX™‐96 Viral RNA Isolation Kit (ThermoFisher Scientific, UK) according to manufacturer\'s instructions, utilizing a MagMAX™ Express 96 Extraction Robot (ThermoFisher Scientific, UK). To determine the analytical sensitivity, a tenfold dilution series (10^−1^--10^−9^) was made of RNA extracted from SVV‐1 isolates NC‐88‐23626 and LA‐97‐1278 (Table [1](#tbed13051-tbl-0001){ref-type="table"}) diluted in nuclease‐free water (NFW) containing carrier RNA (1 μg/μl, Qiagen). RNA dilution series was tested in triplicate using the rRT‐PCR and RT‐LAMP assays.

2.5. Reverse transcription loop‐mediated isothermal amplification {#tbed13051-sec-0007}
-----------------------------------------------------------------

The 25 μl Reverse transcription loop‐mediated isothermal amplification (RT‐LAMP) reaction mix comprised 15 μl of isothermal mastermix ISO‐001 (Optigene Ltd., UK) containing 7.5 units of OptiRT enzyme (Optigene Ltd., UK), 2.5 μl of 10× the primer set to be tested, 2.5 μl NFW and 5 μl of RNA/diluted OS template. Primer sets contained 2.0 μM each of forward and reverse inner primers (FIP and BIP respectively), 0.2 μM each of forward and reverse outer primers (F3 and B3 respectively), and 1.0 μM each of forward and reverse loop primers (LF and LB respectively). The 'wet' assay format containing P1 or P2 was used for bench validation (VK‐001RT‐SVV‐1‐050, Optigene Ltd., UK). Nucleotide positions for all primers in P1 and P2 mapped to GenBank accession no. [DQ641257](DQ641257) are shown in Figure [1](#tbed13051-fig-0001){ref-type="fig"}. RT‐LAMP reactions were performed on a battery powered, portable Genie^®^ II (OptiGene Ltd., UK), at 63°C for 30 min. A positive reaction was signified by an exponential increase in fluorescence (δR). The time to positivity (*T* ~p~) was determined by the peak fluorescence ratio on the amplification rate curve, with a threshold value of 0.02. To confirm the specificity of the SVV‐1 amplicons, anneal temperatures (*T* ~a~) were calculated for all reactions, after a melt curve analysis was carried out by heating RT‐LAMP products to 98°C for 1 min, then cooling to 80°C decreasing at 0.05°C/s. All RT‐LAMP analysis was performed using Genie^®^ Explorer v0.2.1.1 software (OptiGene Ltd., UK).

![Oligonucleotide primers used for RT‐LAMP amplification of SVV‐1. (a) Primer set 1 (P1) targeting the 5′UTR region; (b) Primer set 2 (P2), targeting the VP3‐1 region. Nucleotide positions of the primers in both primer sets (P1 and P2) are mapped to GenBank accession number DQ641257 \[Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](TBED-66-497-g001){#tbed13051-fig-0001}

2.6. Lyophilized RT‐LAMP reagents {#tbed13051-sec-0008}
---------------------------------

Freeze‐dried RT‐LAMP reaction mixes (VK‐DR001RT‐SVV‐1‐100, Optigene Ltd., UK) were prepared to include either primer set 1 (P1) or primer set 2 (P2) using proprietary lyophilization reagents. Each reaction was resuspended with 20 μl of resuspension buffer on use. Five μl of RNA/diluted OS template was subsequently added to each reaction.

2.7. Real‐time reverse transcription PCR {#tbed13051-sec-0009}
----------------------------------------

Real‐time reverse transcription PCR (rRT‐PCR) assays were carried out as described previously (Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}), with primers and a probe targeting the conserved 3D region of SVV‐1, using the SuperScript^®^ III Platinum^®^ One‐Step qRT‐PCR Kit reaction mix on an Applied Biosystems 7500 Fast real‐time PCR instrument (Applied Biosystems, UK).

2.8. Direct detection by RT‐LAMP {#tbed13051-sec-0010}
--------------------------------

Twofold dilutions of cell culture isolates NC‐88‐23626 and LA‐97‐1278 already diluted 1/100 in negative pig epithelium tissue suspension (subsequently referred to as 'neat'), were prepared as template for the RT‐LAMP reaction in the absence of RNA extraction, to evaluate simple sample preparation suitable for field use. Extracted RNA (as described above) from these 'neat' samples was used as a comparison.

3. RESULTS {#tbed13051-sec-0011}
==========

3.1. RT‐LAMP optimization {#tbed13051-sec-0012}
-------------------------

Six primer sets targeting differing regions of the SVV‐1 genome were initially investigated using extracted RNA from the seven SVV‐1 isolates in Table [1](#tbed13051-tbl-0001){ref-type="table"} (data not shown). Only primer sets P1 and P2, targeting the 5′‐UTR and VP3‐1 regions, respectively, produced positive results, with a similar *T* ~p~ across all samples and were consequently chosen for further evaluation. A positive sample was defined when amplification occurred, with a SVV‐1 amplicon‐specific anneal temperature (*T* ~a~) (P1: mean *T* ~a~ 87.9 ± 0.15, P2: mean T~a~ 86.5 ± 0.13 for 35 SVV‐1‐positive RT‐LAMP reactions).

3.2. Analytical sensitivity {#tbed13051-sec-0013}
---------------------------

A log~10~ serial dilution series of RNA extracted from samples NC‐88‐23626 and LA‐97‐1278 was used to compare the analytical sensitivity of the SVV‐1 RT‐LAMP using P1 and P2, with the rRT‐PCR (Table [2](#tbed13051-tbl-0002){ref-type="table"}). A higher analytical sensitivity was observed for P1, compared to P2 for both samples tested. The rRT‐PCR showed higher analytical sensitivity than both primer sets of the RT‐LAMP by at least one log~10~ dilution (P1: LA‐97‐1278), and up to three log~10~ dilutions (P2).

###### 

Analytical sensitivity of the two SVV‐1 RT‐LAMP assays using either P1 or P2 and compared to the rRT‐PCR

  Sample/test         Primer set   Dilution                                                                                                                                                                                                                                
  ------------------- ------------ ---------- ------- ------- ----------------------------------------------- ------------ ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ------------
  NC‐88‐23626                                                                                                                                                                                                                                                              
  RT‐LAMP (*T* ~p~)   P1           07:30      07:20   08:00   09:00                                           12:25        12:45[a](#tbed13051-note-0005){ref-type="fn"}   12:30[a](#tbed13051-note-0005){ref-type="fn"}   No *T* ~p~                                      No *T* ~p~
  P2                  06:55        07:40      09:05   10:35   16:45[a](#tbed13051-note-0005){ref-type="fn"}   No *T* ~p~   No *T* ~p~                                      No *T* ~p~                                      No *T* ~p~                                      
  rRT‐PCR (*C* ~T~)                18.97      22.29   25.67   29.01                                           32.30        35.67                                           38.49                                           40.86[a](#tbed13051-note-0005){ref-type="fn"}   Undet.
  LA‐97‐1278                                                                                                                                                                                                                                                               
  RT‐LAMP (*T* ~p~)   P1           06:50      07:10   08:30   09:05                                           11:20        14:50                                           12:15[a](#tbed13051-note-0005){ref-type="fn"}   No *T* ~p~                                      No *T* ~p~
  P2                  08:05        09:10      10:50   13:35   No *T* ~p~                                      No *T* ~p~   No *T* ~p~                                      No *T* ~p~                                      No *T* ~p~                                      
  rRT‐PCR (*C* ~T~)                17.00      20.24   23.57   26.96                                           30.45        33.74                                           37.19                                           39.85[b](#tbed13051-note-0006){ref-type="fn"}   Undet.

Values are means of three replicates. NC‐88‐23626 and LA‐97‐1278 are SVV‐1 isolates.

P1: primer set 1, P2: primer set 2.

*C* ~T~/*T* ~p~ values for only one well.

*C* ~T~/*T* ~p~ values for only two wells. Undet. *C* ~T~ value undetermined by rRT‐PCR.

John Wiley & Sons, Ltd

3.3. Diagnostic sensitivity and specificity {#tbed13051-sec-0014}
-------------------------------------------

RNA extracted from seven SVV‐1 cell culture isolates diluted 1/100 in negative pig epithelium tissue suspension (Table [1](#tbed13051-tbl-0001){ref-type="table"}), and a panel of other viruses that cause similar clinical signs (SVDV, FMDV, VSNJV, VSIV and ASFV) was used to evaluate the sensitivity and specificity of the SVV‐1 RT‐LAMP using both primer sets. There was 100% agreement between P1 and P2 by RT‐LAMP with the rRT‐PCR for the SVV‐1‐positive samples, where a positive result was observed as early as 5:45 and 6:15 min for P1 and P2, respectively. No false positive results were observed for 10/10 of the known positive virus samples and the negative pig epithelium tissue suspension sample for either primer set.

3.4. Direct detection by RT‐LAMP {#tbed13051-sec-0015}
--------------------------------

Simple preparation of samples was evaluated, where OS samples were added directly, or after dilution in nuclease‐free water (NFW), prior to RT‐LAMP. For P1, the addition of neat OS resulted in complete inhibition of the RT‐LAMP, with no amplification observed (Figure [2](#tbed13051-fig-0002){ref-type="fig"}). The lowest *T* ~p~ was achieved at a 1/20 dilution (*T* ~p~: 8:45 min), an increase in *T* ~p~ of 1:15 min when compared to the addition of extracted RNA. For P2, a positive result was observed for all dilutions, with the lowest *T* ~p~ achieved at a 1/8 dilution (*T* ~p~: 7:28 min), equivalent to the extracted RNA. *T* ~p~ values were similar between dilutions of 1/8--1/20 for both primer sets.

![Comparison of 'wet' and lyophilized reagents using direct detection by RT‐LAMP with primer set 1 (a) and primer set 2 (b). Black bars represent 'wet' reagents and grey bars represent lyophilized reagents. Neat: SVV‐1 sample NC‐88‐23626 diluted 1/100 in negative pig epithelium tissue suspension to simulate a natural original suspension sample. This 'neat' sample was then diluted &frac12;, ¼, 1/8, 1/10, 1/16 and 1/20 in nuclease‐free water (NFW) and compared to extracted RNA from the 'neat' sample as a positive control](TBED-66-497-g002){#tbed13051-fig-0002}

3.5. Evaluation of lyophilized RT‐LAMP reagents {#tbed13051-sec-0016}
-----------------------------------------------

Diagnostic and analytical sensitivity, and direct detection methods were also evaluated using lyophilized reagents and compared with 'wet' reagents. For the seven SVV‐1 samples available, the performance of both assays was comparable (Figure [3](#tbed13051-fig-0003){ref-type="fig"}), and the limit of detection was equivalent when using P1; however for P2, one log~10~ reduction in analytical sensitivity was observed using lyophilized reagents. For both primer sets, an increase in *T* ~p~ ^ ^\> 1 min for all dilutions was observed. When samples were added directly to lyophilized reagents, *T* ~p~ values were comparable at the higher dilutions (1/4--1/20); however when the sample was added either neat (P1 and P2) or at a 1/2 (P1) dilution, a reduction in inhibition was observed, with amplification occurring earlier, than when compared to using 'wet' reagents (Figure [2](#tbed13051-fig-0002){ref-type="fig"}).

![A box‐plot to compare Tp values of 'wet' and lyophilized reagents for primer sets 1 (P1) and 2 (P2) using extracted RNA from the seven SVV‐1 samples. SVV‐1 samples were diluted 1/100 in negative pig epithelium tissue suspension prior to RNA extraction](TBED-66-497-g003){#tbed13051-fig-0003}

4. DISCUSSION {#tbed13051-sec-0017}
=============

Rapid detection of SVV‐1 is important to identify the infectious agent, and to differentiate between clinically indistinguishable notifiable diseases such as FMD. An incorrect diagnosis may have severe consequences, including the type of control strategies implemented and financial implications (Anderson, [2002](#tbed13051-bib-0003){ref-type="ref"}; Ferris, King, Reid, Shaw, & Hutchings, [2006](#tbed13051-bib-0010){ref-type="ref"}). A number of sensitive molecular assays for the detection of SVV‐1 have been previously reported (Bracht et al., [2016](#tbed13051-bib-0006){ref-type="ref"}; Dall Agnol et al., [2017](#tbed13051-bib-0007){ref-type="ref"}; Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}; Gimenez‐Lirola et al., [2016](#tbed13051-bib-0013){ref-type="ref"}; Hales et al., [2008](#tbed13051-bib-0015){ref-type="ref"}); however, samples must be transported to laboratories for testing, delaying the time to result. This study described the development and bench validation of sensitive and specific RT‐LAMP assays for the detection of SVV‐1 that may be performed at the point of sample collection, enabling a positive result in under 9 min.

Six primer sets were designed targeting different conserved regions of the SVV‐1 genome, including the 5′‐UTR, VP3‐1, VP1 and 3D regions, based on available sequences from Genbank and the rRT‐PCR assays previously described (Bracht et al., [2016](#tbed13051-bib-0006){ref-type="ref"}; Dall Agnol et al., [2017](#tbed13051-bib-0007){ref-type="ref"}; Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}; Gimenez‐Lirola et al., [2016](#tbed13051-bib-0013){ref-type="ref"}). The two most sensitive primer sets, P1 and P2, target the 5′‐UTR and VP3‐1 regions, respectively, which have also been the target of choice for molecular diagnostic tests for other picornaviruses, including FMDV (King et al., [2006](#tbed13051-bib-0020){ref-type="ref"}; Reid et al., [2014](#tbed13051-bib-0029){ref-type="ref"}), SVDV (Reid, Ferris, Hutchings, King, & Alexandersen, [2004](#tbed13051-bib-0028){ref-type="ref"}) and human rhinovirus (Bochkov, Grindle, Vang, Evans, & Gern, [2014](#tbed13051-bib-0005){ref-type="ref"}). Both assays were able to demonstrate amplification of neat samples diluted 1/100 in negative pig epithelium tissue suspension in under eight minutes, when RNA was extracted prior to the RT‐LAMP assay. No false positive amplification was observed for the other viruses tested. Diagnostic sensitivity was 100% for both assays when compared to a recently developed rRT‐PCR (Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}), using the seven samples that were available for this study. As this is a small sample size, it is recommended that these assays be further evaluated using more samples of different types, taken from a wider geographical distribution.

The analytical sensitivity of the SVV‐1 RT‐LAMP using primer set P1 was found to be at least one‐log~10~ higher than the analytical sensitivity of the SVV‐1 RT‐LAMP when using primer set P2, for the two samples tested, and at least one‐log~10~ lower than the rRT‐PCR (Fowler et al., [2017](#tbed13051-bib-0012){ref-type="ref"}). However, for the dilutions that were not detected in all replicates by RT‐LAMP, for example 10^−7^ and 10^−8^, high *C* ~T~ values were observed when tested with the rRT‐PCR (\>37 *C* ~T~ average) suggesting a low level of virus was present. Although the SVV‐1 RT‐LAMP demonstrates a slightly lower sensitivity than the rRT‐PCR, samples from clinical cases are likely to contain high viral loads, and therefore RT‐LAMP has the capacity to be a useful tool in the rapid diagnosis of SVV‐1.

To enable the potential of these assays to be employed for rapid detection in the field, simple sample preparation methods were investigated to negate the requirement for RNA extraction, which may be difficult to perform in field conditions. For the rapid detection of FMDV from clinical samples, previous studies demonstrated that a 1/5 dilution of epithelium tissue suspension or serum, and a 1/10 dilution of oesophageal--pharyngeal fluid, in NFW, was sufficient to reduce the inhibitory effect observed by the addition of a neat sample to the RT‐LAMP (Howson et al., [2017](#tbed13051-bib-0018){ref-type="ref"}; Waters et al., [2014](#tbed13051-bib-0033){ref-type="ref"}). This study therefore investigated whether this methodology could also be applied to the SVV‐1 RT‐LAMP assays, using a twofold dilution series. As clinical samples were not available for this study, isolates were diluted 1/100 in negative pig epithelium tissue suspension to simulate an original suspension (OS) sample that would be prepared by homogenization of swine epithelium tissue either in the field, for example using the SVANODIP® Ag Extraction kit (Svanova), or in the laboratory, before testing. When these samples were added directly to the RT‐LAMP, no amplification was observed for P1, and there was delayed amplification when using P2, likely due to contaminants present in the sample causing reaction inhibition. Further dilution of the sample enabled amplification, with an optimum dilution of 1/16 for P1 and 1/8 for P2. Although a slight delay to amplification was evident using these dilutions when compared to using RNA extraction coupled with RT‐LAMP, time from sample receipt to amplification was achieved within 12 min, highlighting the potential of these assays for rapid field diagnosis. However, further validation is required using a variety of field samples, including epithelial tissue samples, serum and vesicular swabs, to check for inhibitory effects from contaminants such as soil and faeces.

To overcome the difficulties of using temperature‐sensitive 'wet' reagents in molecular assays employed in field settings, many studies have evaluated the use of thermostable lyophilized reagents that do not require the maintenance of a cold chain (Armson et al., [2017](#tbed13051-bib-0004){ref-type="ref"}; Goller et al., [2018](#tbed13051-bib-0014){ref-type="ref"}; Howson et al., [2018](#tbed13051-bib-0017){ref-type="ref"}; Semper et al., [2016](#tbed13051-bib-0031){ref-type="ref"}). Lyophilized and 'wet' reagents demonstrated comparable performance to one another when the seven available SVV‐1 samples were tested, and when diluted samples (\>1/4) were added directly to the RT‐LAMP. Additionally, when a sample was added either neat or diluted 1/2 in nuclease‐free water, the amplification inhibition observed with 'wet' reagents was reduced when replaced with lyophilized reagents. This provides an indication that a lyophilized SVV‐1 RT‐LAMP could be utilized as an efficient and rapid diagnostic tool. However, it is recommended that these lyophilized assays are validated on a variety of sample types and viral loads in field settings.

In conclusion, this study describes the development of RT‐LAMP assays for the rapid detection of SVV‐1, suitable for employment in field settings. These assays could be performed alongside field tests for FMD (Ambagala et al., [2016](#tbed13051-bib-0002){ref-type="ref"}; Howson et al., [2017](#tbed13051-bib-0018){ref-type="ref"}, [2018](#tbed13051-bib-0017){ref-type="ref"}; Madi et al., [2012](#tbed13051-bib-0024){ref-type="ref"}; Paixão et al., [2008](#tbed13051-bib-0026){ref-type="ref"}), providing a rapid alternative diagnosis when FMD is negated. RT‐LAMP can be performed on a portable real‐time fluorometer, with results achieved in under 12 min, removing the requirement for RNA extraction. Furthermore, the use of lyophilized reagents enables rapid and simple methodology. Deployment of these RT‐LAMP assays into in situ settings could assist in disease control by enabling simple, rapid and highly sensitive detection of SVV‐1.
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